Literature DB >> 30714569

Outcomes of upper extremity access during fenestrated-branched endovascular aortic repair.

Aleem K Mirza1, Gustavo S Oderich2, Giuliano A Sandri1, Emanuel R Tenorio1, Victor J Davila1, Jussi M Kärkkäinen1, Jan Hofer1, Stephen Cha3.   

Abstract

OBJECTIVE: Upper extremity (UE) access is frequently used during fenestrated-branched endovascular aortic repair (F-BEVAR) to facilitate catheterization of downgoing vessels. Limitations include risk of cerebral embolization and of UE arterial or peripheral nerve injury. The aim of this study was to assess outcomes of F-BEVAR using UE access.
METHODS: We reviewed the clinical data of 334 consecutive patients (74% males; mean age 75 ± 8 years) treated by F-BEVAR for thoracoabdominal aortic aneurysms or pararenal aortic aneurysms between 2007 and 2016. Patients who underwent F-BEVAR with an UE approach for catheterization of the renal and/or mesenteric arteries were included in the study. End points were technical success, mortality, and a composite of access-related complications including cerebral embolization (stroke/transient ischemic attack), peripheral nerve injury, and axillary-brachial arterial complications requiring intervention.
RESULTS: There were 243 patients (73%) treated by F-BEVAR with UE access, including 147 patients (60%) with thoracoabdominal aortic aneurysms and 96 patients (40%) with pararenal aortic aneurysms. A total of 878 renal-mesenteric arteries were incorporated by fenestrations or branches with a mean of 3.6 ± 0.8 vessels per patient. All patients had surgical exposure of the brachial artery. The left side was selected in 228 (94%) and the right side in 15 (6%). The technical success of target vessel incorporation was achieved in 99% of patients (870 of 878). Arterial closure was performed using primary repair in 213 patients (88%) or bovine patch angioplasty in 29 (12%). Patch closure was required in 13% of patients (21 of 159) treated by 10- to 12F sheaths and 8% (7 of 83) of those who had 7- to 8F sheaths (P = .19). There were six deaths (2.5%) at 30 days or within the hospital stay, none owing to access-related complications. Major access-related complication occurred in eight patients (3%), with no difference between the 10- to 12F (6 of 159 [4%]) or 7- to 8F sheaths (2 of 83 [2%]; P = .45). Two patients (1%) had transient median nerve neuropraxia, which resolved within 1 year. One patient (0.5%) required surgical evacuation of an access site hematoma. There were no UE arterial pseudoaneurysms, occlusions, or distal embolizations. Five patients (2%) had strokes (three minor, two major), occurring more frequently with right side (2 of 15 [13%]) as compared with left-sided access (3 of 228 [1%]; P = .03). After a mean follow-up of 38 ± 15 months, there were no other access-related complications or reinterventions.
CONCLUSIONS: UE arterial access with surgical exposure was associated with a low rate of complications in patients treated with F-BEVAR. Closure with patch angioplasty is frequently needed, but there were no arterial occlusions, pseudoaneurysms, or distal embolizations requiring secondary procedures.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebral embolization; F-BEVAR; Upper extremity

Mesh:

Year:  2018        PMID: 30714569     DOI: 10.1016/j.jvs.2018.05.214

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Perioperative neurologic outcomes of right versus left upper extremity access for fenestrated-branched endovascular aortic aneurysm repair.

Authors:  Carla K Scott; Anna L Driessen; Marilisa Soto Gonzalez; Fatemeh Malekpour; Gerardo G Guardiola; Mirza S Baig; Melissa L Kirkwood; Carlos H Timaran
Journal:  J Vasc Surg       Date:  2021-09-28       Impact factor: 4.860

2.  A Stopped Pilot Study of the ProGlide Closure Device After Transbrachial Endovascular Interventions.

Authors:  Max M Meertens; Michiel W de Haan; Geert W H Schurink; Barend M E Mees
Journal:  J Endovasc Ther       Date:  2019-07-09       Impact factor: 3.487

3.  Stabilization of a steerable sheath during retrograde access to antegrade-oriented branches in complex endovascular aortic aneurysm repair.

Authors:  Charlotte C Lemmens; Barend M E Mees; Michiel W de Haan; Geert Willem H Schurink
Journal:  J Vasc Surg Cases Innov Tech       Date:  2020-04-16

Review 4.  Peri-Operative Management of Patients Undergoing Fenestrated-Branched Endovascular Repair for Juxtarenal, Pararenal and Thoracoabdominal Aortic Aneurysms: Preventing, Recognizing and Treating Complications to Improve Clinical Outcomes.

Authors:  Andrea Xodo; Mario D'Oria; Bernardo Mendes; Luca Bertoglio; Kevin Mani; Mauro Gargiulo; Jacob Budtz-Lilly; Michele Antonello; Gian Franco Veraldi; Fabio Pilon; Domenico Milite; Cristiano Calvagna; Filippo Griselli; Jacopo Taglialavoro; Silvia Bassini; Anders Wanhainen; David Lindstrom; Enrico Gallitto; Luca Mezzetto; Davide Mastrorilli; Sandro Lepidi; Randall DeMartino
Journal:  J Pers Med       Date:  2022-06-21

5.  European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia.

Authors:  Luke G Terlouw; Adriaan Moelker; Jan Abrahamsen; Stefan Acosta; Olaf J Bakker; Iris Baumgartner; Louis Boyer; Olivier Corcos; Louisa Jd van Dijk; Mansur Duran; Robert H Geelkerken; Giulio Illuminati; Ralph W Jackson; Jussi M Kärkkäinen; Jeroen J Kolkman; Lars Lönn; Maria A Mazzei; Alexandre Nuzzo; Felice Pecoraro; Jan Raupach; Hence Jm Verhagen; Christoph J Zech; Desirée van Noord; Marco J Bruno
Journal:  United European Gastroenterol J       Date:  2020-04-16       Impact factor: 4.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.